Specific binding of intravenous immunoglobulin products to tau peptide fragments

International Immunopharmacology

Volumn 21, Issue 2, 2014, Pages 279-282

  Smith, Lynnae M ^a   Coffey, Mary P ^a   Loeffler, David A ^a  

^a WILLIAM BEAUMONT HOSPITAL   (United States)

Author keywords

Alzheimer's disease; Antibody binding; ELISA; Intravenous immunoglobulin; IVIG; Tau

Indexed keywords

HUMAN IMMUNOGLOBULIN; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; PEPTIDE FRAGMENT; TAU PROTEIN; ANTIBODY; PROTEIN BINDING;

AMINO TERMINAL SEQUENCE; ARTICLE; CARBOXY TERMINAL SEQUENCE; DRUG PROTEIN BINDING; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; MICROTUBULE; NEUROTOXICITY; PRIORITY JOURNAL; IMMUNOLOGY;

ANTIBODIES; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; PEPTIDE FRAGMENTS; PROTEIN BINDING; TAU PROTEINS;

EID: 84902004051     PISSN: 15675769     EISSN: 18781705     Source Type: Journal    
DOI: 10.1016/j.intimp.2014.05.009     Document Type: Article

References (31)

1. M. von Bergen, P. Friedhoff, J. Biernat, J. Heberle, E.M. Mandelkow, and E. Mandelkow Assembly of tau protein into Alzheimer paired helical filaments depends on a local sequence motif ((306)VQIVYK(311)) forming beta structure Proc Natl Acad Sci U S A 97 2000 5129 5134 (Pubitemid 30313683)
2. M. Tokimasa, K. Minoura, S. Hiraoka, K. Tomoo, M. Sumida, and T. Taniguchi et al. Importance of local structures of second and third repeat fragments of microtubule-binding domain for tau filament formation FEBS Lett 579 2005 3481 3486 (Pubitemid 40897680)
3. K. Tomoo, T.M. Yao, K. Minoura, S. Hiraoka, M. Sumida, and T. Taniguchi et al. Possible role of each repeat structure of the microtubule-binding domain of the tau protein in in vitro aggregation J Biochem 138 2005 413 423 (Pubitemid 41703693)
4. B. Combs, and T.C. Gamblin FTDP-17 tau mutations induce distinct effects on aggregation and microtubule interactions Biochemistry 51 2012 8597 8607
5. T. Taniguchi, M. Sumida, S. Hiraoka, K. Tomoo, T. Kakehi, and K. Minoura et al. Effects of different anti-tau antibodies on tau fibrillogenesis: RTA-1 and RTA-2 counteract tau aggregation FEBS Lett 579 2005 1399 1404 (Pubitemid 40289187)
6. G. Carmel, E.M. Mager, L.I. Binder, and J. Kuret The structural basis of monoclonal antibody Alz50's selectivity for Alzheimer's disease pathology J Biol Chem 271 1996 32789 32795 (Pubitemid 27008707)
7. S.M. Ward, D.S. Himmelstein, J.K. Lancia, and L.I. Binder Tau oligomers and tau toxicity in neurodegenerative disease Biochem Soc Trans 40 2012 667 671
8. R.W. Berry, A. Abraha, S. Lagalwar, N. LaPointe, T.C. Gamblin, and V.L. Cryns et al. Inhibition of tau polymerization by its carboxy-terminal caspase cleavage fragment Biochemistry 42 2003 8325 8331 (Pubitemid 36858993)
9. P.S. Aisen Tarenflurbil: a shot on goal Lancet Neurol 7 2008 468 469
10. C. Holmes, D. Boche, D. Wilkinson, G. Yadegarfar, V. Hopkins, and A. Bayer et al. Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial Lancet 372 2008 216 223 (Pubitemid 351978111)
11. P.H. St George-Hyslop, and J.C. Morris Will anti-amyloid therapies work for Alzheimer's disease? Lancet 372 2008 180 182 (Pubitemid 351997437)
12. G.K. Wilcock, and M.M. Esiri Plaques, tangles and dementia. A quantitative study J Neurol Sci 56 1982 343 356 (Pubitemid 12002356)
13. P.V. Arriagada, J.H. Growdon, E.T. Hedley-Whyte, and B.T. Hyman Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease Neurology 42 1992 631 639
14. K.A. Josephs, J.L. Whitwell, Z. Ahmed, M.M. Shiung, S.D. Weigand, and D.S. Knopman et al. Beta-amyloid burden is not associated with rates of brain atrophy Ann Neurol 63 2008 204 212 (Pubitemid 351355299)
15. C.M. Wischik, P. Bentham, D.J. Wischik, and K.M. Seng Tau aggregation inhibitor (TAI) therapy with remberTM arrests disease progression in mild and moderate Alzheimer's disease over 50 weeks Alzheimers Dement 4 2008 T167
16. K. Santacruz, J. Lewis, T. Spires, J. Paulson, L. Kotilinek, and M. Ingelsson et al. Tau suppression in a neurodegenerative mouse model improves memory function Science 309 2005 476 481 (Pubitemid 40994688)
17. T.L. Spires, J.D. Orne, K. SantaCruz, R. Pitstick, G.A. Carlson, and K.H. Ashe et al. Region-specific dissociation of neuronal loss and neurofibrillary pathology in a mouse model of tauopathy Am J Pathol 168 2006 1598 1607
18. T. Jaworski, S. Kügler, and F. Van Leuven Modeling of tau-mediated synaptic and neuronal degeneration in Alzheimer's disease Int J Alzheimers Dis 2010 2010 573138
19. N.R. Relkin, P. Szabo, B. Adamiak, T. Burgut, C. Monthe, and R.W. Lent et al. 18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease Neurobiol Aging 30 2009 1728 1736
20. R. Dodel, A. Rominger, P. Bartenstein, F. Barkhof, K. Blennow, and S. Förster et al. Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial Lancet Neurol 12 2013 233 243
21. R.C. Dodel, Y. Du, C. Depboylu, H. Hampel, L. Frölich, and A. Haag et al. Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer's disease J Neurol Neurosurg Psychiatry 75 2004 1472 1474 (Pubitemid 39279821)
22. L.M. Smith, M.P. Coffey, A.C. Klaver, and D.A. Loeffler Intravenous immunoglobulin products contain specific antibodies to recombinant human tau protein Int Immunopharmacol 16 2013 424 428
23. S. Counts, S. Perez, B. He, and E. Mufson Intravenous immunoglobulin reduces tau pathology and preserves neuroplastic gene expression in the 3xTg mouse model of Alzheimer's disease Current Alz. Res. 2014 in press
24. I. St-Amour, I. Paré, C. Tremblay, K. Coulombe, R. Bazin, and F. Calon IVIG protects the 3xTg-AD mouse model of Alzheimer's disease from memory deficit and Abeta pathology J Neuroinflammation 11 2014 54
25. Y. Shen, L. Lue, L. Yang, A. Roher, Y. Kuo, and R. Strohmeyer et al. Complement activation by neurofibrillary tangles in Alzheimer's disease Neurosci Lett 305 2001 165 168 (Pubitemid 32525831)
26. N. Kfoury, B.B. Holmes, H. Jiang, D.M. Holtzman, and M.I. Diamond Trans-cellular propagation of Tau aggregation by fibrillar species J Biol Chem 287 2012 19440 19451
27. L. Liu, V. Drouet, J.W. Wu, M.P. Witter, S.A. Small, and C. Clelland et al. Trans-synaptic spread of tau pathology in vivo PLoS One 7 2012 e31302
28. P.K. Krishnamurthy, Y. Deng, and E.M. Sigurdsson Mechanistic studies of antibody-mediated clearance of tau aggregates using an ex vivo brain slice model Front Psychiatry 2 2011 59
29. J. Douglas, L. Gardner, and M.C. Levin Antibodies to an intracellular antigen penetrate neuronal cells and cause deleterious effects J Clin Cell Immunol 4 2013 134
30. J. Gu, E.E. Congdon, and E.M. Sigurdsson Two novel tau antibodies targeting the 396/404 region are primarily taken up by neurons and reduce tau protein pathology J Biol Chem 288 2013 33081 33095
31. E.E. Congdon, J. Gu, H.B. Sait, and E.M. Sigurdsson Antibody uptake into neurons occurs primarily via clathrin-dependent Fcγ receptor endocytosis and is a prerequisite for acute tau protein clearance J Biol Chem 288 2013 35452 35465